Sample size requirements for studies of treatment effects on Beta-Cell function in newly diagnosed type 1 diabetes

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Lachin, John M ^a   McGee, Paula L ^a   Greenbaum, Carla J ^b   Palmer, Jerry ^c   Pescovitz, Mark D ^d   Gottlieb, Peter ^e   Skyler, Jay ^f  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO DENVER   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; DRUG DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; CHILD; CLINICAL STUDY; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; SAMPLE SIZE; SCHOOL CHILD; STATISTICAL ANALYSIS; TREATMENT OUTCOME; AGE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AREA UNDER CURVE; C-PEPTIDE; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SAMPLE SIZE; YOUNG ADULT;

EID: 80755159540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026471     Document Type: Article

References (23)

1. Atkinson MA, Maclaren NK, (1994) The pathenogenesis of insulin-dependant diabetes mellitus. N Engl J Med 331: 1428-1436.
2. Ludvigsson J. The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Technol 3: 320-330, 2009.
3. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, et al. (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53: 250-64. Erratum: Diabetes 53: 1934, 2004.
4. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, et al. (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31: 1966-71.
5. Food and Drug Administration (2008) Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Accessed April 27, 2011, at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf.
6. Pescovitz M, Greenbaum C, Krause-Steinrauf H, Becker D, Gitelman S, Goland R, Gottlieb P, Marks J, McGee P, Moran A, Raskin P, Rodriguez H, Schatz D, Wherrett D, Wilson D, Lachin J, Skyler JS, (2009) Preservation of Beta-Cell Function by B-Lymphocyte Depletion with Rituximab in Patients with New Onset Autoimmune Diabetes. N Engl J Med 361: 2143-52.
7. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum C, Wilson D, Rodriguez H, Schatz D, Moran A, Lachin JM, Skyler JS, (2010) Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes. Diabetes Care 33: 826-832.
8. Bartlett, MS, (1947) The Use of Transformations. Biometrics 3: 39-52.
9. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W, (1996) Applied linear statistical methods. 4th ed Chicago Irwin, 1996.
10. Laird N, (1983) Further comparative analyses of pretest-posttest research designs. The American Statistician 37: 329-330.
11. Thode HC, (2002) Testing for normality New York Marcel Dekker.
12. Shapiro SS, Wilk MB, (1965) An Analysis of Variance Test for Normality (complete samples). Biometrika 52: 591-611.
13. White H, (1980) A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica, 48: 817-838.
14. Lachin JM, (1981) Introduction to sample size determination and power analysis for clinical trials. Control. Clin. Trials 2: 93-113.
15. Wolfe R, Carlin JB, (1999) Sample-size calculation for a log-transformed outcome measure. Control. Clin. Trials 20: 547-554.
16. Conover WJ, Iman RL, (1981) Rank Transformations as a Bridge Between Parametric and Nonparametric Statistics. The American Statistician 35: 124-129.
17. Demidenko E, (2004) Mixed Models: Theory and Applications Hoboken, New Jersey John Wiley & Sons.
18. Box GEP, Cox DR, (1964) An analysis of transformations. J Roy Statist Soc Ser B 26: 211-252.
19. Sakia RM, (1992) The Box-Cox transformation technique: a review. The Statistician 41: 169-178.
20. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698.
21. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-608.
22. Raz I, Elias D, Avron A, Tamir M, Metzger M, et al. (2001) β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 358: 1749-1753.
23. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, et al. (2008) GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes. N Engl J Med 359: 1909-1920.